引用本文
  • 付新新,李兆申,金震东,陈海涛,朱伟,蔡全才.髓过氧化物酶在吸烟与胰腺癌发病关系中的作用[J].第二军医大学学报,2012,33(2):183-185    [点击复制]
  • FU Xin-xin,LI Zhao-shen,JIN Zhen-dong,CHEN Hai-tao,ZHU Wei,CAI Quan-cai.Role of myeloperoxidase in relationship between smoking and risk of pancreatic cancer[J].Acad J Sec Mil Med Univ,2012,33(2):183-185   [点击复制]
【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 955次   下载 981 本文二维码信息
码上扫一扫!
髓过氧化物酶在吸烟与胰腺癌发病关系中的作用
付新新1,2,李兆申1,2,金震东2,陈海涛1,2,朱伟1,2,蔡全才1,2*
0
(1. 第二军医大学临床流行病学与循证医学中心,上海 200433
2. 第二军医大学长海医院消化内科,上海 200433
*通信作者)
摘要:
目的 探讨髓过氧化物酶(MPO)在吸烟与胰腺癌发病关系中的作用。 方法 采用病例-对照研究设计。病例组为71例经病理证实的新发胰腺导管腺癌患者,对照组为71例按照性别、年龄进行匹配的健康人群。采用自制调查表进行面对面问卷调查。调查内容包括年龄、性别、体质指数(BMI)、吸烟、饮酒、糖尿病史等。采集研究对象治疗前的静脉血,采用酶联免疫分析方法 检测其血浆MPO浓度。以对照组MPO浓度的中位数作为界值,将研究对象MPO浓度分为高和低两组。采用多元非条件Logistic回归分析方法 分别探讨吸烟与胰腺癌、吸烟与高MPO浓度胰腺癌、吸烟与低MPO浓度胰腺癌的关系。 结果 在控制年龄、性别、饮酒、BMI的情况下,吸烟者发生胰腺癌的风险升高(OR=2.74, 95%CI: 1.12-6.74; P=0.028);将病例组按照MPO浓度(196 IU/L)进行分层后,发现吸烟与高MPO浓度胰腺癌有关(OR=3.81, 95%CI: 1.17-12.44; P=0.026),但与低MPO浓度胰腺癌无相关(OR=2.51, 95%CI: 0.82-7.72; P=0.108)。 结论 吸烟可能导致胰腺癌的发病风险升高。血浆MPO浓度升高可能在吸烟与胰腺癌关系中起作用。
关键词:  胰腺肿瘤  吸烟  髓过氧化物酶  病例对照研究
DOI:10.3724/SP.J.1008.2012.0183
投稿时间:2011-06-29修订日期:2011-08-01
基金项目:国家自然科学基金(30972532).
Role of myeloperoxidase in relationship between smoking and risk of pancreatic cancer
FU Xin-xin1,2,LI Zhao-shen1,2,JIN Zhen-dong2,CHEN Hai-tao1,2,ZHU Wei1,2,CAI Quan-cai1,2*
(1. Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
2. Center for Clinical Epidemiology and Evidence Based Medicine, Second Military Medical University, Shanghai 200433, China
*Corresponding author.)
Abstract:
Objective To study the role of myeloperoxidase (MPO) in the relationship between smoking and risk of pancreatic cancer. Methods A case-control study was adopted in the present study. Totally 71 patients with newly diagnosed pancreatic ductal adenocarcinoma (pathologically confirmed) and 71 age- and sex-matched healthy persons were included. All the subjects were interviewed using a self-designed questionnaire concerning the age, sex, body mass index (BMI), smoking, alcohol consumption, and history of diabetes mellitus. The venous blood samples were collected from patients before treatment and enzyme-linked immunosorbent assay was used to measure the plasma MPO; the subjects were divided into high and low MPO groups based on the median MPO value of controls. Unconditional logistic regression model was used to study the relationship of smoking with risk of pancreatic cancer, risk of pancreatic cancer with high plasma MPO, and risk of pancreatic cancer with low plasma MPO. Results After adjusted for age, sex, alcohol consumption, and BMI, smoking significantly increased the risk of pancreatic cancer (OR=2.74, 95%CI: 1.12-6.74; P=0.028). Besides, smoking was also significantly associated with increased risk of pancreatic cancer with high plasma MPO (>196 IU/L) (OR=3.81, 95%CI: 1.17-12.44; P=0.026), and was not significantly associated with the risk of pancreatic cancer with low plasma MPO (≤196 IU/L) (OR=2.51, 95%CI: 0.82-7.72; P=0.108). Conclusion Smoking may increase the risk of pancreatic cancer. High plasma MPO level may play an important role in the relationship between smoking and risk of pancreatic cancer.
Key words:  pancreatic neoplasms  smoking  myeloperoxidase  case-control studies